
Curaleaf stock has been a hot topic in the cannabis industry, with its stock quote fluctuating over time.
As of our last update, Curaleaf's stock price was around $6.50 per share.
Curaleaf's market capitalization is over $4 billion, making it one of the largest cannabis companies in the world.
The company has seen significant growth in recent years, with its revenue increasing by over 200% in 2020.
Curaleaf's stock performance is closely tied to the overall cannabis market, which has experienced significant volatility in recent years.
If this caught your attention, see: Subaru Ticker Symbol
Expand your knowledge: Stryker Stock Symbol
Company Information
Curaleaf is a leading multi-state cannabis operator in the United States.
Founded in 2010, the company has a strong presence in the industry with a growing portfolio of brands and products.
Curaleaf has a diverse range of products, including flower, concentrates, edibles, and topicals, catering to various customer preferences.
About
We're a company that's been around for over 10 years, with a mission to provide innovative solutions to our customers.
Our team consists of experienced professionals with a combined total of over 50 years of experience in the industry.
We have a strong focus on customer satisfaction, with a customer retention rate of over 90%.
We're headquartered in a major city, with a large office space that can accommodate over 200 employees.
We've received numerous awards and recognition for our work, including being named one of the fastest-growing companies in the country.
Managers and Directors
Let's take a closer look at the Managers and Directors of Curaleaf Holdings, Inc. The CEO, Boris Jordan, is 59 years old and has been in the role since August 15, 2024.
Boris Jordan also serves as the Chairman of the company, a position he has held since December 31, 2014. He's been with the company for over 9 years.
Edward Kremer is the Director of Finance/CFO and has been in this role since August 7, 2022. Unfortunately, his age is not publicly disclosed.
The Chief Tech/Sci/R&D Officer, Jessie Kater, is also a member of the management team, but her age and start date are not available.
Here's a list of the Directors/Board Members:
These are the key people behind the scenes at Curaleaf Holdings, Inc.
Market Performance
The US cannabis industry is projected to continue its rapid expansion, with revenue expected to exceed $50 billion by 2030.
The industry's growth is expected to be steady, despite recent challenges, and is valued at approximately $30 billion.
RISE Dispensaries, a cannabis retail chain, continues to grow its medical cannabis retail footprint in Florida, despite weed being illegal in the state.
The US cannabis industry is showing resilience, with projected growth and a significant market value.
You might enjoy: Ishares Us Preferred Stock Etf Pff
Financials
Curaleaf's net sales have been steadily increasing, with a notable jump from $1.22B in 2024 to $1.46B in 2025. This growth is a promising sign for investors.
The company's net income, however, has been experiencing losses, with a high of -$281.20 million in 2023. This is a significant decrease from the previous year's losses.
Here's a breakdown of Curaleaf's net sales and net income for 2024 and 2025:
Curaleaf's net debt has also been increasing, with a high of $61.15B in 2024. This is a significant concern for investors.
Financials
Financials play a crucial role in a company's overall performance. The data from 2024 and 2025 shows a mixed bag of results.
Net sales for 2024 and 2025 are projected to be $1.46B and $1.4B, respectively. This is an increase from the previous year's $1.29B.
Losses are expected to continue, with a net income of -$142M in 2024 and -$136M in 2025. These losses are a significant concern for investors.
Net debt is also a pressing issue, with a total of $510M in 2024 and $490M in 2025. This is a significant increase from the previous year's $677M.
Here's a summary of the key financial metrics for 2024 and 2025:
The data suggests that the company is facing significant financial challenges. The increasing net debt and losses are major concerns that need to be addressed.
News and Updates
Curaleaf Holdings, Inc. has been making headlines in the cannabis industry. The company's stock has been affected by the DEA's decision to postpone rescheduling hearings, causing cannabis stocks to pull back.
Curaleaf's third-quarter revenue was $330.5 million, a significant increase from previous quarters. The company's net loss narrowed significantly, with a loss of $44 million from continuing operations.
Curaleaf has been expanding its operations, opening a new dispensary in Miami, Florida, which is its 66th dispensary in the state. The company has also secured a new $40 million revolving credit facility to support its ongoing working capital needs.
Here are some key dates to keep in mind:
Curaleaf's efforts to expand its operations and secure funding are a positive sign for the company's future growth.
Analyst Insights
The average brokerage rating for Curaleaf Holdings, Inc. is 1.75, based on 8 recommendations from leading investment websites.
This rating suggests a generally positive outlook from the analysts who have weighed in on the stock. The current average target price is $5.24.
Here are some recent analyst updates for Curaleaf:
These updates demonstrate that analysts are optimistic about the company's prospects, with several recommending a "buy" rating.
Analysts' Recommendations
Analysts' recommendations can be a valuable tool for investors, providing insights into a company's potential future performance.
The Average Brokerage Rating (ABR) is a calculated average of the actual recommendations made by brokerage firms for a given stock. In the case of Curaleaf Holdings, Inc., the ABR is 1.75.
The ABR is updated regularly, and it's interesting to note that it remained the same last week, at 1.75. This suggests that analysts' opinions on the stock have not changed recently.
The number of recommendations included in the ABR is 8, which may not be a large sample size but still provides some insight into analysts' views on the stock.
Analysts' price targets can also be a useful indicator of a stock's potential future performance. For Curaleaf Holdings, Inc., the average target price is $5.24.
The industry in which a company operates can also have an impact on its stock performance. Curaleaf Holdings, Inc. operates in the Medical - Products industry, which is ranked 87 out of 251 by the ABR.
Here is a table summarizing the key facts about Curaleaf Holdings, Inc.'s ABR:
New Era

As we move into a new era for cannabis stocks, it's essential to understand the current landscape and potential opportunities. The US cannabis industry is valued at approximately $30 billion and is projected to exceed $50 billion by 2030.
Curaleaf Holdings, Inc. is one company that has been making waves in the industry. They recently reported Q3 revenue of $330.5 million and secured a new $40 million revolving credit facility to support their ongoing working capital needs. This financial stability could be a game-changer for the company.
Despite the challenges facing the industry, there are still opportunities for growth. For example, Curaleaf has been expanding its operations, opening new dispensaries in states like Florida. In fact, they recently opened their 66th dispensary in the state, a significant milestone for the company.
Here are some key statistics on Curaleaf's recent activity:
The future of cannabis stocks is uncertain, but one thing is clear: companies like Curaleaf are pushing forward with innovative strategies and financial stability. As we move into this new era, it will be exciting to see how these companies adapt and thrive.
See what others are reading: Publicly Traded Outdoor Companies
Frequently Asked Questions
Is Curaleaf a good stock to buy right now?
Curaleaf has a strong buy recommendation from 8 brokerage firms, with an average price target of $5.24, suggesting potential growth. However, individual results may vary, and it's essential to do your own research before making an investment decision.
Why is CURLF stock dropping?
CURLF stock is dropping due to regulatory pressures and declining revenue, with the company reporting a net loss of $42.3 million in Q3 2024. Net revenue dropped 1% year-over-year to $330.5 million, contributing to the stock's decline.
Is Curaleaf in debt?
As of September 2024, Curaleaf's total debt on the balance sheet is $0.84 Billion USD, indicating that the company does have debt. However, the specifics of their financial situation and debt management can be found in their official financial reports.
Featured Images: pexels.com


